Dermatology Drug is used in the management and treatment of diseases related to skin. Acne, psoriasis, and dermatitis are some common skin diseases.
The global market for Dermatology Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
In the US market, the major manufacturers are AbbVie, Johnson & Johnson, Bayer, Galderma, Bristol-Myers Squibb, Novartis, Pfizer, Merz Pharma, Valeant and Leo Pharma.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Dermatology Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Dermatology Drug by region & country, by Type, and by Application.
The Dermatology Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dermatology Drug.
Market Segmentation
By Company
AbbVie
Johnson & Johnson
Bayer
Galderma
Bristol-Myers Squibb
Novartis
Pfizer
Merz Pharma
Valeant
LEO Pharma
GlaxoSmithKline
Segment by Type:
External Use
Oral
Injection
Segment by Application
Psoriasis
Skin Infections
Acne
Dermatitis
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Dermatology Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Dermatology Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Dermatology Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Dermatology Drug Product Introduction
1.2 Global Dermatology Drug Market Size Forecast
1.3 Dermatology Drug Market Trends & Drivers
1.3.1 Dermatology Drug Industry Trends
1.3.2 Dermatology Drug Market Drivers & Opportunity
1.3.3 Dermatology Drug Market Challenges
1.3.4 Dermatology Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Dermatology Drug Players Revenue Ranking (2023)
2.2 Global Dermatology Drug Revenue by Company (2019-2024)
2.3 Key Companies Dermatology Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Dermatology Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Dermatology Drug
2.6 Dermatology Drug Market Competitive Analysis
2.6.1 Dermatology Drug Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Dermatology Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dermatology Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 External Use
3.1.2 Oral
3.1.3 Injection
3.2 Global Dermatology Drug Sales Value by Type
3.2.1 Global Dermatology Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Dermatology Drug Sales Value, by Type (2019-2030)
3.2.3 Global Dermatology Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Psoriasis
4.1.2 Skin Infections
4.1.3 Acne
4.1.4 Dermatitis
4.1.5 Others
4.2 Global Dermatology Drug Sales Value by Application
4.2.1 Global Dermatology Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Dermatology Drug Sales Value, by Application (2019-2030)
4.2.3 Global Dermatology Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Dermatology Drug Sales Value by Region
5.1.1 Global Dermatology Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Dermatology Drug Sales Value by Region (2019-2024)
5.1.3 Global Dermatology Drug Sales Value by Region (2025-2030)
5.1.4 Global Dermatology Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Dermatology Drug Sales Value, 2019-2030
5.2.2 North America Dermatology Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Dermatology Drug Sales Value, 2019-2030
5.3.2 Europe Dermatology Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Dermatology Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Dermatology Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Dermatology Drug Sales Value, 2019-2030
5.5.2 South America Dermatology Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Dermatology Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Dermatology Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Dermatology Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Dermatology Drug Sales Value
6.3 United States
6.3.1 United States Dermatology Drug Sales Value, 2019-2030
6.3.2 United States Dermatology Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Dermatology Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Dermatology Drug Sales Value, 2019-2030
6.4.2 Europe Dermatology Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Dermatology Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Dermatology Drug Sales Value, 2019-2030
6.5.2 China Dermatology Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Dermatology Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Dermatology Drug Sales Value, 2019-2030
6.6.2 Japan Dermatology Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Dermatology Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Dermatology Drug Sales Value, 2019-2030
6.7.2 South Korea Dermatology Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Dermatology Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Dermatology Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Dermatology Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Dermatology Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Dermatology Drug Sales Value, 2019-2030
6.9.2 India Dermatology Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Dermatology Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AbbVie
7.1.1 AbbVie Profile
7.1.2 AbbVie Main Business
7.1.3 AbbVie Dermatology Drug Products, Services and Solutions
7.1.4 AbbVie Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.1.5 AbbVie Recent Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Profile
7.2.2 Johnson & Johnson Main Business
7.2.3 Johnson & Johnson Dermatology Drug Products, Services and Solutions
7.2.4 Johnson & Johnson Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.2.5 Johnson & Johnson Recent Developments
7.3 Bayer
7.3.1 Bayer Profile
7.3.2 Bayer Main Business
7.3.3 Bayer Dermatology Drug Products, Services and Solutions
7.3.4 Bayer Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.3.5 Galderma Recent Developments
7.4 Galderma
7.4.1 Galderma Profile
7.4.2 Galderma Main Business
7.4.3 Galderma Dermatology Drug Products, Services and Solutions
7.4.4 Galderma Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.4.5 Galderma Recent Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Profile
7.5.2 Bristol-Myers Squibb Main Business
7.5.3 Bristol-Myers Squibb Dermatology Drug Products, Services and Solutions
7.5.4 Bristol-Myers Squibb Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Bristol-Myers Squibb Recent Developments
7.6 Novartis
7.6.1 Novartis Profile
7.6.2 Novartis Main Business
7.6.3 Novartis Dermatology Drug Products, Services and Solutions
7.6.4 Novartis Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Recent Developments
7.7 Pfizer
7.7.1 Pfizer Profile
7.7.2 Pfizer Main Business
7.7.3 Pfizer Dermatology Drug Products, Services and Solutions
7.7.4 Pfizer Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.7.5 Pfizer Recent Developments
7.8 Merz Pharma
7.8.1 Merz Pharma Profile
7.8.2 Merz Pharma Main Business
7.8.3 Merz Pharma Dermatology Drug Products, Services and Solutions
7.8.4 Merz Pharma Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.8.5 Merz Pharma Recent Developments
7.9 Valeant
7.9.1 Valeant Profile
7.9.2 Valeant Main Business
7.9.3 Valeant Dermatology Drug Products, Services and Solutions
7.9.4 Valeant Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.9.5 Valeant Recent Developments
7.10 LEO Pharma
7.10.1 LEO Pharma Profile
7.10.2 LEO Pharma Main Business
7.10.3 LEO Pharma Dermatology Drug Products, Services and Solutions
7.10.4 LEO Pharma Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.10.5 LEO Pharma Recent Developments
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Profile
7.11.2 GlaxoSmithKline Main Business
7.11.3 GlaxoSmithKline Dermatology Drug Products, Services and Solutions
7.11.4 GlaxoSmithKline Dermatology Drug Revenue (US$ Million) & (2019-2024)
7.11.5 GlaxoSmithKline Recent Developments
8 Industry Chain Analysis
8.1 Dermatology Drug Industrial Chain
8.2 Dermatology Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Dermatology Drug Sales Model
8.5.2 Sales Channel
8.5.3 Dermatology Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
AbbVie
Johnson & Johnson
Bayer
Galderma
Bristol-Myers Squibb
Novartis
Pfizer
Merz Pharma
Valeant
LEO Pharma
GlaxoSmithKline
*If Applicable.